ELTP outlines plans to introduce a new anticoagulant by 2028 amid NASDAQ uplisting efforts.
Elite Pharmaceuticals announced a 2028 target for launching its new anticoagulant during its Q1 fiscal 2027 earnings call. The timeline aligns with the company’s ongoing NASDAQ uplisting process, which management described as progressing as planned.
The company did not provide prior guidance on the anticoagulant’s development timeline or market expectations. Elite’s focus remains on advancing its pipeline while completing regulatory and exchange requirements for uplisting.
No immediate market reaction was disclosed in the earnings call summary.